Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism.

Nelson B Watts John P Bilezikian Henry G Bone Bart Lyman Clarke Douglas Denham Michael A Levine Michael Mannstadt Munro Peacock Jeffrey H Rothman Tamara J Vokes Mark L WarrenShaoming YinNicole SherryDolores M Shoback

Published in: Journal of the Endocrine Society (2023)

6 years of rhPTH(1-84) treatment was associated with sustained improvements in biochemical parameters, a reduction in the percentage of patients with hypercalciuria, stable renal function, and decreased supplement requirements. rhPTH(1-84) was well tolerated; no new safety signals were identified.

Keyphrases

recombinant human